Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/14/22
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate UpdatesAccesswire • 03/07/22
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las VegasAccesswire • 03/01/22
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in DogsAccesswire • 02/16/22
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines AgencyAccesswire • 02/15/22
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in DogsAccesswire • 02/10/22
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)Accesswire • 02/01/22
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo TherapeuticsAccesswire • 01/24/22
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, FloridaAccesswire • 01/12/22
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsAccesswire • 01/04/22
Jaguar Health Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in DogsAccesswire • 12/22/21
FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In DogsBenzinga • 12/22/21
JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health HigherInvestorPlace • 12/21/21
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDAAccesswire • 12/21/21
Jaguar Health's Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company's Focus on Rare Diseases & Orphan DrugsAccesswire • 12/20/21
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health's Italian Subsidiary, for Short Bowel SyndromeAccesswire • 12/13/21